(NYSE:BKKT), – GAAP revenue1 of $402.2 million, up 27% year-over-year– GAAP net loss of $23.2 million, primarily due to 2024 registered direct offering warrant liability mark-to-market– Adjusted EBITDA of $28.7 million, up 241% year-over-year– Ended the quarter with $64.4 million in cash and restricted cash with no long-term debt– Completed sale of Loyalty business October […]

(NASDAQ:ONMD), MINNEAPOLIS, Nov. 10, 2025 (GLOBE NEWSWIRE) — OneMedNet Corporation (Nasdaq: ONMD) (“OneMedNet” or the “Company”), a leader in AI-empowered Real-World Data (RWD), today announced that it will demonstrate its next-generation iRWD(TM) platform at ISPOR Europe. Built on the Palantir Technologies Foundry ecosystem, the platform enables life sciences, diagnostics, and medical device organizations to securely

(NASDAQ:VERO), TORONTO, Nov. 10, 2025 (GLOBE NEWSWIRE) — Venus Concept Inc. (“Venus Concept” or the “Company”), a global leader in medical aesthetic technology, announced today that it has received a 510(k) clearance from the U.S. Food and Drug Administration (“FDA”) to market the Venus NOVA(TM), the Company's next-generation multi-application platform designed to redefine non-invasive treatments

(NasdaqGM:WVE), WVE-007, an INHBE GalNAc-siRNA for obesity designed to drive fat loss while preserving muscle mass, achieved dose-dependent, mean reductions of Activin E of up to 85% in INLIGHT clinical trial, exceeding levels that led to weight loss and prevention of rebound weight gain following cessation of GLP-1 in preclinical models Activin E reduction in

(NASDAQ:CYTK), Three Late Breaking Science Presentations from MAPLE-HCM Provide Additional Data Including Responder Analyses, Patient Reported Outcomes, and Cardiac Biomarkers SOUTH SAN FRANCISCO, Calif., Nov. 10, 2025 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that additional data from MAPLE-HCM (Metoprolol vs Aficamten in Patients with LVOT Obstruction on Exercise Capacity in HCM) were

All brelovitug dose regimens studied were well tolerated Results will be presented at The Liver Meeting(R) 2025 of AASLD Additional preclinical data presented on brelovitug mechanisms of action REDWOOD CITY, Calif., Nov. 10, 2025 (GLOBE NEWSWIRE) — Bluejay Therapeutics, a clinical-stage biopharmaceutical company dedicated to developing potentially life-changing therapeutics for serious viral and liver diseases,

(NASDAQ:RAIL), Delivered 42% revenue growth year-over-year Strong gross margins of 15.1%, expansion of 80 basis points Reaffirming Adjusted EBITDA guidance for full year CHICAGO, Nov. 10, 2025 (GLOBE NEWSWIRE) — FreightCar America, Inc. (NASDAQ: RAIL) (“FreightCar America” or the “Company”), a diversified manufacturer and supplier of railroad freight cars, railcar parts and components, today reported

(NASDAQ:SUNE), Q3 2025 Select Highlights Sales Increased 29% to $19.0 Million Gross Profit Rose to $7.2 Million; Gross Margin Improved to 38% Net Loss Narrowed to $0.4 Million Adjusted EBITDA Improved to $898,000 Unrestricted Cash Rose to $5.4 Million – Highest Level Since 2022 Total Debt Declined 59% from December 31, 2024 RONKONKOMA, N.Y., Nov.

(NASDAQ:LYEL), LYL273 has demonstrated a 67% overall response rate, an 83% disease control rate, and a manageable safety profile at the highest dose level studied to date in patients with refractory metastatic colorectal cancer enrolled in an ongoing U.S. Phase 1 clinical trial LYL273 is a GCC-targeted CAR T-cell product candidate armed with enhancements designed

(NASDAQ:SGRY), BRENTWOOD, Tenn., Nov. 10, 2025 (GLOBE NEWSWIRE) — Surgery Partners, Inc. (NASDAQ:SGRY) (“Surgery Partners” or the “Company”), a leading short-stay surgical facility owner and operator, today announced results for the third quarter ended September 30, 2025. Third Quarter 2025 Financial Highlights (All comparisons are year-over-year unless otherwise noted) Revenue increased 6.6% for the third